戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ation exposes the host to antigens from both preerythrocytic and blood stages, and induced immunity m
2  screened for total immunoglobulin G against preerythrocytic and erythrocytic antigens.
3 ect protective biological effects induced by preerythrocytic and/or blood-stage candidate vaccines if
4 ing significant efficacy when expressing the preerythrocytic antigen insert multiple epitope-thrombos
5  part to infrequent high-level antibodies to preerythrocytic antigens and AMA-1.
6 date subunit malaria vaccines expressing six preerythrocytic antigens linked together to produce a 32
7 terile protective immune responses targeting preerythrocytic antigens.
8 h-level immunoglobulin G (IgG) antibodies to preerythrocytic circumsporozoite protein (CSP) and liver
9 se data introduce a new target of protective preerythrocytic immune responses, PyHEP 17 and its P. fa
10 ce are more susceptible to Plasmodium yoelii preerythrocytic infection than BALB/cJ mice.
11 impanzee adenovirus 63 (ChAd63) encoding the preerythrocytic insert multiple epitope thrombospondin-r
12  two; all vaccines express parts of the same preerythrocytic malaria antigen, the Plasmodium berghei
13 esence of adaptive cell-mediated immunity to preerythrocytic malaria antigens in volunteers from Mali
14 of an early immune response directed against preerythrocytic malaria parasites that are required for
15 cted as a first step in the development of a preerythrocytic malaria vaccine.
16 (Pf) is a prime goal in the development of a preerythrocytic malaria vaccine.
17 evaluate liver-stage protection by candidate preerythrocytic malaria vaccines.
18 approach for identifying target antigens for preerythrocytic malaria vaccines.
19                         Fourteen epitopes of preerythrocytic malarial antigens known to mediate cytot
20 ith unstable transmission, IgG antibodies to preerythrocytic P. falciparum antigens vary in subjects
21 t of early immunity directed against malaria preerythrocytic parasites and suggest that gammadelta T
22 ng vaccine classes currently in development: preerythrocytic (PEV), blood stage (BSV), and transmissi
23  (IgG) antibodies to three vaccine candidate preerythrocytic Plasmodium falciparum antigens were eval
24 a should facilitate our understanding of the preerythrocytic Plasmodium life cycle stages and the dev
25 unity has emerged as a critical component of preerythrocytic protection that might be leveraged to de
26 ritical effector cells in protection against preerythrocytic stage malaria, including the potent prot
27 laria vaccine that prevents infection at the preerythrocytic stage.
28 esponses against a pool of peptides from the preerythrocytic-stage antigen, PkCSP.
29 ia species Plasmodium knowlesi including two preerythrocytic-stage antigens, the circumsporozoite pro
30 lii sporozoites or with plasmid DNA encoding preerythrocytic-stage P. yoelii antigens.
31  the HIV PIs lopinavir and saquinavir affect preerythrocytic-stage parasite development in vitro.
32  with a mixture of DNA plasmids encoding two preerythrocytic-stage proteins and two erythrocytic-stag
33 at ChAd63 and MVA expressing PvTRAP are good preerythrocytic-stage vaccine candidates with potential
34                                The effect on preerythrocytic stages has not yet been investigated.
35   We then evaluated the effect of HIV PIs on preerythrocytic stages in vivo using the rodent parasite
36 cation and cloning of genes expressed in the preerythrocytic stages lag far behind.
37 t parasite play a protective role during the preerythrocytic stages of malaria.
38 at CD8(+) T cells play in protection against preerythrocytic stages of malaria; however, there is mou
39      The latter approach completely bypasses preerythrocytic stages, enabling a direct comparison of
40 d protection is mediated by immunity against preerythrocytic stages.
41  throughout the life cycle, with emphasis on preerythrocytic stages.
42 panel of HIV PIs in vitro for effects on the preerythrocytic stages.
43  have been widely used to assess efficacy of preerythrocytic vaccine candidates in small proof-of-con
44  protein, FMP011, has been manufactured as a preerythrocytic vaccine to induce an immune response tha
45 ite vaccine, the "gold standard" for malaria preerythrocytic vaccines, was sporozoite-neutralizing an
46 ium life cycle stages and the development of preerythrocytic vaccines.